* patients who do not require inpatient admission for covid-19 infection. * patients who require invasive mechanical ventilation at time of enrollment. * a pre-existing condition or use of a medication that, in the opinion of the site investigator, may place the individual at a substantially increased risk due to study participation. * pregnancy or breast feeding (lactating women who agree to discard breast milk from day 1 until two weeks after the last study product is given are not excluded). * allergy to dupilumab or its excipients. * received any of the following in the two weeks prior to screening as treatment of covid-19: * small molecule tyrosine kinase inhibitors (e.g. imatinib, gefitinib, acalabrutinib, etc.); * monoclonal antibodies targeting cytokines (e.g., tnf inhibitors, anti-interleukin-1 \[il-1\], anti-il-6 \[or sarilumab\], etc.); * monoclonal antibodies targeting t-cells or b-cells as treatment for covid-19; * any other immunomodulatory (other than steroids) medications within 5 half-lives or 30 days prior to randomization. * current acute parasitic helminth infection or history of chronic parasitic infection. * history of ocular scleritis, uveitis, keratitis or recent (\<6 months) eye injury (chemical or traumatic), infection or vascular occlusion. * have received any live vaccine (that is, live attenuated) within 4 weeks before screening, or intend to receive a live vaccine (or live attenuated) during the study. note: use of non-live (inactivated) vaccinations is allowed for all subjects.

* patients who do not require inpatient admission for covid-19 infection. * patients who require invasive mechanical ventilation at time of enrollment. * a pre-existing condition or use of a medication that, in the opinion of the site investigator, may place the individual at a substantially increased risk due to study participation. * pregnancy or breast feeding (lactating women who agree to discard breast milk from day 1 until two weeks after the last study product is given are not excluded). * allergy to dupilumab or its excipients. * received any of the following in the two weeks prior to screening as treatment of covid-19: * small molecule tyrosine kinase inhibitors (e.g. imatinib, gefitinib, acalabrutinib, etc.); * monoclonal antibodies targeting cytokines (e.g., tnf inhibitors, anti-interleukin-1 \[il-1\], anti-il-6 \[or sarilumab\], etc.); * monoclonal antibodies targeting t-cells or b-cells as treatment for covid-19; * any other immunomodulatory (other than steroids) medications within 5 half-lives or 30 days prior to randomization. * current acute parasitic helminth infection or history of chronic parasitic infection. * history of ocular scleritis, uveitis, keratitis or recent (\<6 months) eye injury (chemical or traumatic), infection or vascular occlusion. * have received any live vaccine (that is, live attenuated) within 4 weeks before screening, or intend to receive a live vaccine (or live attenuated) during the study. note: use of non-live (inactivated) vaccinations is allowed for all subjects.

patients who do not require inpatient admission for covid-19 infection. patients who require invasive mechanical ventilation at time of enrollment. a pre-existing condition or use of a medication that, in the opinion of the site investigator, may place the individual at a substantially increased risk due to study participation. pregnancy or breast feeding (lactating women who agree to discard breast milk from day 1 until two weeks after the last study product is given are not excluded). allergy to dupilumab or its excipients. received any of the following in the two weeks prior to screening as treatment of covid-19: small molecule tyrosine kinase inhibitors (e.g. imatinib, gefitinib, acalabrutinib, etc.); monoclonal antibodies targeting cytokines (e.g., tnf inhibitors, anti-interleukin-1 [il-1], anti-il-6 [or sarilumab], etc.); monoclonal antibodies targeting t-cells or b-cells as treatment for covid-19; any other immunomodulatory (other than steroids) medications within 5 half-lives or 30 days prior to randomization. current acute parasitic helminth infection or history of chronic parasitic infection. history of ocular scleritis, uveitis, keratitis or recent (<6 months) eye injury (chemical or traumatic), infection or vascular occlusion. have received any live vaccine (that is, live attenuated) within 4 weeks before screening, or intend to receive a live vaccine (or live attenuated) during the study. note: use of non-live (inactivated) vaccinations is allowed for all subjects.

patients who do not require inpatient admission for covid-19 infection. patients who require invasive mechanical ventilation at time of enrollment. a pre-existing condition or use of a medication that, in the opinion of the site investigator, may place the individual at a substantially increased risk due to study participation. pregnancy or breast feeding (lactating women who agree to discard breast milk from day 1 until two weeks after the last study product is given are not excluded). allergy to dupilumab or its excipients. received any of the following in the two weeks prior to screening as treatment of covid-19: small molecule tyrosine kinase inhibitors (e.g. imatinib, gefitinib, acalabrutinib, etc.); monoclonal antibodies targeting cytokines (e.g., tnf inhibitors, anti-interleukin-1 [il-1], anti-il-6 [or sarilumab], etc.); monoclonal antibodies targeting t-cells or b-cells as treatment for covid-19; any other immunomodulatory (other than steroids) medications within 5 half-lives or 30 days prior to randomization. current acute parasitic helminth infection or history of chronic parasitic infection. history of ocular scleritis, uveitis, keratitis or recent (<6 months) eye injury (chemical or traumatic), infection or vascular occlusion. have received any live vaccine (that is, live attenuated) within 4 weeks before screening, or intend to receive a live vaccine (or live attenuated) during the study. note: use of non-live (inactivated) vaccinations is allowed for all subjects.

- patients who do not require inpatient admission for covid-19 infection. - patients who require invasive mechanical ventilation at time of enrollment. - a pre-existing condition or use of a medication that, in the opinion of the site investigator, may place the individual at a substantially increased risk due to study participation. - pregnancy or breast feeding (lactating women who agree to discard breast milk from day 1 until two weeks after the last study product is given are not excluded). - allergy to dupilumab or its excipients. - received any of the following in the two weeks prior to screening as treatment of covid-19: - small molecule tyrosine kinase inhibitors (e.g. baricitinib, imatinib, gefitinib, acalabrutinib, etc.); - monoclonal antibodies targeting cytokines (e.g., tnf inhibitors, anti-interleukin-1 [il-1], anti-il-6 [tocilizumab or sarilumab], etc.); - monoclonal antibodies targeting t-cells or b-cells as treatment for covid-19; - any other immunomodulatory (other than steroids) medications within 5 half-lives or 30 days prior to randomization. - current acute parasitic helminth infection or history of chronic parasitic infection. - history of ocular scleritis, uveitis, keratitis or recent (<6 months) eye injury (chemical or traumatic), infection or vascular occlusion. - have received any live vaccine (that is, live attenuated) within 4 weeks before screening, or intend to receive a live vaccine (or live attenuated) during the study. note: use of non-live (inactivated) vaccinations is allowed for all subjects.

- patients who do not require inpatient admission for covid-19 infection. - patients who require invasive mechanical ventilation at time of enrollment. - a pre-existing condition or use of a medication that, in the opinion of the site investigator, may place the individual at a substantially increased risk due to study participation. - pregnancy or breast feeding (lactating women who agree to discard breast milk from day 1 until two weeks after the last study product is given are not excluded). - allergy to dupilumab or its excipients. - received any of the following in the two weeks prior to screening as treatment of covid-19: - small molecule tyrosine kinase inhibitors (e.g. baricitinib, imatinib, gefitinib, acalabrutinib, etc.); - monoclonal antibodies targeting cytokines (e.g., tnf inhibitors, anti-interleukin-1 [il-1], anti-il-6 [tocilizumab or sarilumab], etc.); - monoclonal antibodies targeting t-cells or b-cells as treatment for covid-19; - any other immunomodulatory (other than steroids) medications within 5 half-lives or 30 days prior to randomization. - current acute parasitic helminth infection or history of chronic parasitic infection. - history of ocular scleritis, uveitis, keratitis or recent (<6 months) eye injury (chemical or traumatic), infection or vascular occlusion. - have received any live vaccine (that is, live attenuated) within 4 weeks before screening, or intend to receive a live vaccine (or live attenuated) during the study. note: use of non-live (inactivated) vaccinations is allowed for all subjects.